Abstract:Following the publication of this article, an interested reader drew to the authors' attention that the flow cytometric (FCM) plots in Fig. 2A on p. 2278 showing the 'Dasatinib' and 'CA‐4' experiments were duplicates of each other. After having re‐examined their original data, and due to the overall similarity of the data, the authors have realized that these data were inadvertently assembled incorrectly in the figure. They realize that they also made a further mistake regarding the writing of the ratios of mitochondrial membrane‐depolarized HO‐8910 cells for these FCM plots (essentially, these were written the wrong way around): The percentage of mitochondrial membrane‐depolarized HO‐8910 cells should have been written as 22.50% for the dasatinib‐treated cells (the centre‐left FCM plot) and 15.71% for the CA‐4‐treated cells (centre‐right plot). A revised version of Fig. 2 now showing alternative data for the FCM experiments shown in Fig. 2A, is shown on the next page. Note that the errors made in terms of assembling the data in Fig. 2A did not greatly affect either the results or the conclusions reported in this paper, and all the authors agree with the publication of this corrigendum. The authors regret that these errors went unnoticed prior to the publication of their article, and are grateful to the Editor of Oncology Reports for granting them this opportunity to publish a corrigendum. Furthermore, they apologize to the readership for any inconvenience caused. [Oncology Reports 29: 2275‐2282, 2013; DOI: 10.3892/or.2013.2405]

Artemisinin Derivatives Inactivate Cancer-Associated Fibroblasts Through Suppressing TGF-β Signaling in Breast Cancer

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Correction To: Dihydroartemisinin Inhibits TCTP-dependent Metastasis in Gallbladder Cancer

Dihydroartemisinin Inhibits Tctp-Dependent Metastasis In Gallbladder Cancer (Vol 36, 68, 2017)

Erratum: Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

Retraction: Chinese Herbal Medicine Suppresses Invasion-Promoting Capacity of Cancer-Associated Fibroblasts in Pancreatic Cancer

Correction: Corrigendum: Dihydroartemisinin Prevents Breast Cancer-Induced Osteolysis Via Inhibiting Both Breast Cancer Cells and Osteoclasts

IL-6 Secreted by Cancer-Associated Fibroblasts Induces Tamoxifen Resistance in Luminal Breast Cancer

Correction To: Suppressive Effects of Plumbagin on Invasion and Migration of Breast Cancer Cells Via the Inhibition of STAT3 Signaling and Down-Regulation of Inflammatory Cytokine Expressions

[Corrigendum] Dihydroartemisinin Suppresses Proliferation, Migration, the Wnt/β‑catenin Pathway and EMT Via TNKS in Gastric Cancer

Correction: Shi, H., et al. Arctigenin Attenuates Breast Cancer Progression through Decreasing GM-CSF/TSLP/STAT3/β-Catenin Signaling. Int. J. Mol. Sci. 2020, 21, 6357

Correction To: Methylseleninic Acid Suppresses Breast Cancer Growth Via the JAK2/STAT3 Pathway

Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling: Erratum

[Corrigendum] Inhibition of MDA-MB-231 Breast Cancer Cell Migration and Invasion Activity by Andrographolide Via Suppression of Nuclear Factor-Κb-dependent Matrix Metalloproteinase-9 Expression

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Corrigendum: β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-Pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling

[Corrigendum] Cancer‑associated fibroblasts from invasive breast cancer have an attenuated capacity to secrete collagens.

Retraction Note: Inhibition effects of acridone on the growth of breast cancer cells in vivo

[Corrigendum] Ethyl gallate suppresses proliferation and invasion in human breast cancer cells via Akt‑NF‑κB signaling

Erratum: FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis

[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‐4 in vitro and in vivo